Immunosuppressive treatment results in patients with primary IgA nephropathy in Turkiye; the data from TSN-GOLD working group

Basit Öğe Kaydı
dc.authorid0000-0003-1185-9737
dc.contributor.authorOruç, Ayşegül
dc.contributor.authorTürkmen, Aydın
dc.contributor.authorBaştürk, Taner
dc.contributor.authorCebeci, Egemen
dc.contributor.authorTurgutalp, Kenan
dc.contributor.authorÇetinkaya, Hakkı
dc.contributor.authorÜzerk Kibar, Müge
dc.contributor.authorSeyahi, Nurhan
dc.contributor.authorTatar, Erhan
dc.contributor.authorErgül, Metin
dc.contributor.authorDerici, Ülver
dc.contributor.authorAylı, Mehmet Deniz
dc.contributor.authorPınar, Musa
dc.contributor.authorBakar, Betül
dc.contributor.authorKazancıoğlu, Rümeyza
dc.contributor.authorYıldız, Abdülmecit
dc.contributor.authorDirim, Ahmet Burak
dc.contributor.authorYılmaz, Zülfükar
dc.contributor.authorTürkmen, Kültigin
dc.contributor.authorTunca, Onur
dc.contributor.authorKoç, Mehmet
dc.contributor.authorKutlay, Sim
dc.contributor.authorMicozkadıoğlu, Hasan
dc.contributor.authorAzak, Alper
dc.contributor.authorBoztepe, Burcu
dc.contributor.authorÜstündağ, Sedat
dc.contributor.authorŞafak Öztürk, Seda
dc.contributor.authorÜnsal, Abdulkadir
dc.contributor.authorKaradağ, Serhat
dc.contributor.authorŞahin, Gülizar
dc.contributor.authorCoşgun Yenigün, Ezgi
dc.contributor.authorEren, Necmi
dc.contributor.authorGüllülü, Mustafa
dc.contributor.authorGürsu, Meltem
dc.contributor.authorÖztürk, Savaş
dc.contributor.authorŞumnu, Abdullah
dc.date.accessioned2024-05-24T10:48:25Z
dc.date.available2024-05-24T10:48:25Z
dc.date.issued2024
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractBackground: Immunoglobulin A (IgA) nephropathy (IgAN) treatment consists of maximal supportive care and, for high-risk individuals, immunosuppressive treatment (IST). There are conflicting results regarding IST. Therefore, we aimed to investigate IST results among IgAN patients in Turkiye. Method: The data of 1656 IgAN patients in the Primary Glomerular Diseases Study of the Turkish Society of Nephrology Glomerular Diseases Study Group were analyzed. A total of 408 primary IgAN patients treated with IST (65.4% male, mean age 38.4 ± 12.5 years, follow-up 30 (3–218) months) were included and divided into two groups according to treatment protocols (isolated corticosteroid [CS] 70.6% and combined IST 29.4%). Treatment responses, associated factors were analyzed. Results: Remission (66.7% partial, 33.7% complete) was achieved in 74.7% of patients. Baseline systolic blood pressure, mean arterial pressure, and proteinuria levels were lower in responsives. Remission was achieved at significantly higher rates in the CS group (78% vs. 66.7%, p = 0.016). Partial remission was the prominent remission type. The remission rate was significantly higher among patients with segmental sclerosis compared to those without (60.4% vs. 49%, p = 0.047). In the multivariate analysis, MEST-C S1 (HR 1.43, 95% CI 1.08–1.89, p = 0.013), MEST-C T1 (HR 0.68, 95% CI 0.51–0.91, p = 0.008) and combined IST (HR 0.66, 95% CI 0.49–0.91, p = 0.009) were found to be significant regarding remission. Conclusion: CS can significantly improve remission in high-risk Turkish IgAN patients, despite the reliance on non-quantitative endpoints for favorable renal outcomes. Key predictors of remission include baseline proteinuria and specific histological markers. It is crucial to carefully weigh the risks and benefits of immunosuppressive therapy for these patients.
dc.identifier.citationOruç, A., Şumnu, A., Türkmen, A., Baştürk, T., Cebeci, E., Turgutalp, K. ... Öztürk, S. (2024). Immunosuppressive treatment results in patients with primary IgA nephropathy in Turkiye; the data from TSN-GOLD working group. Renal Failure, 46(1). http://dx.doi.org/10.1080/0886022X.2024.2341787
dc.identifier.doi10.1080/0886022X.2024.2341787
dc.identifier.issn0886-022X
dc.identifier.issn1525-6049
dc.identifier.issue1
dc.identifier.pmid38637275
dc.identifier.scopus2-s2.0-85190809699
dc.identifier.scopusqualityQ2
dc.identifier.urihttp://dx.doi.org/10.1080/0886022X.2024.2341787
dc.identifier.urihttps://hdl.handle.net/20.500.12511/12499
dc.identifier.volume46
dc.identifier.wos001205022800001en_US
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorŞumnu, Abdullah
dc.language.isoen
dc.relation.ispartofRenal Failureen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsAttribution-NonCommercial 4.0 International*
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/*
dc.subjectIga Nephropathy
dc.subjectImmunosuppressive Treatment
dc.subjectOutcome
dc.subjectRemission
dc.subjectTurkiye
dc.titleImmunosuppressive treatment results in patients with primary IgA nephropathy in Turkiye; the data from TSN-GOLD working group
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Şumnu-Abdullah-2024.pdf
Boyut:
4.07 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu